Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TfNP181a
- Development stage
- Preclinical
- Lead developer
- The Ohio State University
- Modality
- Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
TfNP181a is a transferrin-conjugated nanoparticle delivery system encapsulating synthetic precursor microRNA-181a (miR-181a). Developed by researchers at The Ohio State University, it is designed to target acute myeloid leukemia (AML) cells, which often overexpress the transferrin receptor. The nanoparticle consists of a polyethylenimine (PEI) core complexed with miR-181a, surrounded by a lipid layer (DOPE, linoleic acid, and DMPE-mPEG) for protection and cellular uptake. Once delivered, miR-181a downregulates the expression of KRAS and NRAS, thereby inhibiting MAPK signaling. This mechanism sensitizes AML cells to chemotherapy agents like daunorubicin.
- Other names
- transferrin-conjugated miR-181a nanoparticlesTfNP-miR-181aTfNP-miR181aTfNP-miR 181a
02
Targets
NRAS (Neuroblastoma RAS viral oncogene homolog)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on TfNP181a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TfNP181a.